Table 4.
Multivariable Cox regression analyses
| Overall |
Women |
Men |
||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Lenient rate controla | 0.84 (0.52–1.36) | 0.47 | 0.57 (0.26–1.25) | 0.16 | 1.00 (0.50–2.00) | 0.99 |
| Duration of AF per month | 1.01 (1.00–1.01) | 0.004 | 1.03 (1.01–1.04) | <0.001 | ||
| Female sex | 1.87 (1.15–3.03) | 0.011 | ||||
| NT-proBNP per 100 | 1.03 (1.01–1.04) | 0.001 | 1.08 (1.03–1.13) | <0.001 | ||
| hsTroponin-T | 1.02 (1.01–1.04) | 0.003 | 1.09 (1.04–1.13) | <0.001 | ||
| LAVI (mL/m2) | 1.09 (1.05–1.14) | <0.001 | ||||
| Duration AF ⋅ LAVI | 1.00 (0.99–1.00) | 0.031 | ||||
| NT-proBNP hsTroponin-T | 0.99 (0.99–1.00) | 0.016 | ||||
AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; LAVI, left atrial volume index; NT-proBNP, N-terminal pro B-type natriuretic peptide.